Bayer confident about Monsanto deal

• Despite delays, Bayer (OTCPK:BAYRY) remains confident about completing its $66B takeover of Monsanto (NYSE:MON) by the end of the year.
• The drugmaker will only seek EU approval for the transaction in Q2 after regulators there requested more information.
• Meanwhile, Bayer's crops and consumer-care units failed to boost profit last quarter, leaving prescription drugs as its sole engine of growth.